Rhythm Pharmaceuticals 3Q 2026: Revenue $92.13M, Net income ($42.35M), EPS ($0.61) — 10-Q Summary

What happened

Rhythm Pharmaceuticals reported third-quarter 2026 revenue of $92.13 million, up 79.6% year over year. Its net loss narrowed to $42.35 million from $54.28 million, and diluted loss per share improved to $0.61 from $0.82. IMCIVREE sales grew 80%, supported by higher U.S. and international sales.

Confirmed

Global impact / market context

Faster sales growth and a smaller loss suggest the business is gaining revenue while spending still exceeds income. If the trend continues, additional sales could help cover costs; launches and clinical trials also require investment, so they may affect future cash available and the timing of profitability.

Analyst inference

The quarter combines commercial progress with ongoing drug-development risk. IMCIVREE is already being sold in multiple markets, while planned European launches and trials depend on future execution and decisions. Investors therefore have both near-term sales growth and longer-term research spending to weigh.

Analyst inference

What to watch

1. Track whether IMCIVREE revenue growth continues in coming quarters, including whether sales from the acquired hypothalamic obesity launch add to U.S. and international demand. Analyst inference
2. Watch for the planned pivotal Phase 3 trial of bivamelagon by year-end 2026; a pivotal trial is a major study intended to support approval. Proposed
3. Follow enrollment in the RM-718 Prader-Willi syndrome study and progress toward European launches planned for 2027, as both could shape future costs and sales. Confirmed

Evidence

• Original source link unavailable